Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS AUGUST ISSUE PUBLISHED
  • AUGUST 2020 Issue has been successfully launched on 1 August 2020.

Abstract

BIO-EQUIVALENCE STUDY OF TWO ORAL LEVAMISOLE-OXYCLOZANIDE FORMULATIONS (NILZAN® AND CLOZISTONE®) IN CALVES

Ashraf Elkomy* and Mohamed Aboubakr

ABSTRACT

The present study was designed to assess the comparative bio-equivalence of Nilzan® and Clozistone® in healthy calves after oral administration of both products in a dose of (7.5 mg levamisole Hcl/kg b.wt. and 15 mg oxyclozanide/kg b.wt). Ten calves were divided into two groups (each contains 5 calves). The first group was designed to study the pharmacokinetics of Nilzan ®, while the 2nd group was designed to study the pharmacokinetics of Clozistone®. Each calf in both groups was administered orally with (7.5 mg levamisole Hcl/kg b.wt. and 15 mg oxyclozanide/kg b.wt). Blood samples were obtained from the jugular vein and collected immediately before and at 0.15, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours after a single oral administration. The disposition kinetics of levamisole Hcl in Nilzan® and Clozistone® revealed that, the maximum blood concentrations [Cmax] were 1.15 and 1.04 μg/ml and attained at [tmax] of 1.21 and 1.22 hours, respectively. The disposition kinetics of oxyclozanide in Nilzan® and Clozistone® revealed that, the maximum blood concentrations [Cmax] were 9.81 and 9.11 μg/ml and attained at [tmax] of 17.98 and 18.29 hours, respectively. In conclusion: Clozistone® is bioequivalent to Nilzan® since the ratios of Cmax, AUC0-36 and AUC0-∞ (T/R) for levamisole Hcl were 0.90, 0.82 and 0.80 respectively and the ratios of Cmax, AUC0-192 and AUC0-∞ (T/R) for oxyclozanide were 0.92, 0.91 and 0.91 respectively. These are within the Bio-equivalence acceptance range. Nilzan® and Clozistone® are therefore bioequivalent and interchangeable in calves.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More